XuanYuan Biotechnology has recently declared the successful closure of its Pre-A round funding, amassing tens of millions of yuan. These funds are earmarked for propelling the deployment of AI-powered precision diagnosis and treatment solutions, bolstering the development of core technology platforms, and broadening the company's product portfolio. Since its inception in 2021, XuanYuan Biotechnology has been dedicated to addressing unmet needs in clinical decision-making, cultivating a distinctive development model underpinned by its proprietary platform. Its competitive edge stems from its technological prowess and talent pool, having forged a robust technological framework and engaged in partnerships with several leading hospitals. Regarding its product strategy, XuanYuan Biotechnology has adopted a structure of 'one validated, implemented product + multiple scalable transformation pathways', centered on clinical decision-making scenarios. Commencing with a thyroid cancer detection product, which has received applications and certifications across multiple regions, the company is now actively pursuing review applications and overseas certifications. Concurrently, the company is making steady progress in the preparatory work for multiple product pipelines, identifying innovative targets, and undertaking collaborative research. Furthermore, XuanYuan Biotechnology is actively involved in constructing the industry ecosystem and setting standards, with the ambition of establishing an intelligent diagnosis and treatment platform. The company's founder expressed that following the funding, they will expedite the verification and implementation processes for their core products, enhance platform capabilities, and harness AI to better support clinical decision-making, ultimately benefiting a broad spectrum of patients.